Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

Veeva Announces Fiscal 2021 First Quarter Results


Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal first quarter ended April 30, 2020.

"We are incredibly proud to serve the life sciences industry as they pursue diagnostics, treatments, and cures for COVID-19 with unprecedented speed," said CEO Peter Gassner. "Thanks to the Veeva team for all the incredible innovation and execution that's enabling our customers' rapid move to digital so they can continue their critical work helping healthcare professionals and patients."

Fiscal 2021 First Quarter Results:

"Focused execution and our ability to adapt quickly in the face of change enabled us to deliver results above plan in Q1," said CFO Tim Cabral. "Looking ahead, we will continue to invest in our growing product portfolio as the industry increasingly looks to Veeva as one of its most strategic partners across R&D and commercial."

Recent Highlights:

Financial Outlook:

Veeva is providing guidance for its fiscal second quarter ending July 31, 2020 as follows:

Veeva is providing guidance for its fiscal year ending January 31, 2021 as follows:

Conference Call Information

What:

Veeva's Fiscal 2021 First Quarter Results Conference Call

When:

Thursday, May 28, 2020

Time:

1:30 p.m. PT (4:30 p.m. ET)

Live Call:

1-833-502-0495, domestic

 

1-778-560-2571, international

 

Conference ID 669 0227

Webcast:

ir.veeva.com

Investor Presentation Details

An investor presentation providing additional information and analysis can be found at ir.veeva.com.

___________

(1) This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled "Non-GAAP Financial Measures" and the tables entitled "Reconciliation of GAAP to Non-GAAP Financial Measures" below for details.

(2) Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the second fiscal quarter ending July 31, 2020 or fiscal year ending January 31, 2021 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 875 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva has more than 390 Commercial Cloud customers and more than 570 Development Cloud customers. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Forward-looking Statements

This release contains forward-looking statements, including the quotations from management, the statements in "Financial Outlook," and other statements regarding Veeva's future performance, outlook, and guidance and the assumptions underlying those statements, market growth, the benefits from the use of Veeva's solutions, our strategies, and general business conditions. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including (i) the impact of the worldwide outbreak of COVID-19 (including the impact to the life sciences industry, impact on general economic conditions, and government responses, restrictions, and actions related to the pandemic); (ii) breaches in our security measures or unauthorized access to our customers' data; (iii) our expectation that the future growth rate of our revenues will decline; (iv) competitive factors, including but not limited to pricing pressures, consolidation among our competitors, entry of new competitors, the launch of new products and marketing initiatives by our existing competitors, and difficulty securing rights to access, host or integrate with complementary third party products or data used by our customers; (v) the rate of adoption of our newer solutions and the results of our efforts to sustain or expand the use and adoption of our more established applications, like Veeva CRM; (vi) fluctuation of our results, which may make period-to-period comparisons less meaningful; (vii) our ability to integrate Crossix Systems Inc. and Physicians World LLC into our business and achieve the expected benefits of the acquisitions; (viii) loss of one or more customers, particularly any of our large customers; (ix) system unavailability, system performance problems, or loss of data due to disruptions or other problems with our computing infrastructure; (x) our ability to attract and retain highly skilled employees and manage our growth effectively; (xi) failure to sustain the level of profitability we have achieved in the past as our costs increase; (xii) adverse changes in the life sciences industry, including as a result of customer mergers; (xiii) adverse changes in economic, regulatory, or market conditions, including with respect to natural disasters or actual or threatened public health emergencies; (xiv) a decline in new subscriptions that may not be immediately reflected in our operating results due to the ratable recognition of our subscription revenue; and (xv) pending, threatened, or future legal proceedings and related expenses.

Additional risks and uncertainties that could affect Veeva's financial results are included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's filing on Form 10-K for the period ended January 31, 2020. This is available on the company's website at veeva.com under the Investors section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

 

 

April 30,
2020

 

January 31,
2020

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

720,776

 

 

$

476,733

 

Short-term investments

660,199

 

 

610,015

 

Accounts receivable, net

235,923

 

 

389,690

 

Unbilled accounts receivable

37,269

 

 

32,817

 

Prepaid expenses and other current assets

21,105

 

 

21,869

 

Total current assets

1,675,272

 

 

1,531,124

 

Property and equipment, net

52,886

 

 

54,752

 

Deferred costs, net

34,176

 

 

35,585

 

Lease right-of-use assets

46,923

 

 

49,132

 

Goodwill

438,529

 

 

438,529

 

Intangible assets, net

129,403

 

 

134,601

 

Deferred income taxes, noncurrent

11,701

 

 

11,870

 

Other long-term assets

15,729

 

 

16,184

 

Total assets

$

2,404,619

 

 

$

2,271,777

 

 

 

 

 

Liabilities and stockholders' equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

15,041

 

 

$

19,420

 

Accrued compensation and benefits

27,064

 

 

25,619

 

Accrued expenses and other current liabilities

23,405

 

 

21,620

 

Income tax payable

4,441

 

 

5,613

 

Deferred revenue

470,262

 

 

468,887

 

Lease liabilities

10,127

 

 

10,013

 

Total current liabilities

550,340

 

 

551,172

 

Deferred income taxes, noncurrent

1,673

 

 

2,417

 

Lease liabilities, noncurrent

42,430

 

 

44,815

 

Other long-term liabilities

9,140

 

 

7,779

 

Total liabilities

603,583

 

 

606,183

 

Stockholders' equity:

 

 

 

Class A common stock

2

 

 

1

 

Class B common stock

?

 

 

?

 

Additional paid-in capital

792,660

 

 

745,475

 

Accumulated other comprehensive income

2,146

 

 

460

 

Retained earnings

1,006,228

 

 

919,658

 

Total stockholders' equity

1,801,036

 

 

1,665,594

 

Total liabilities and stockholders' equity

$

2,404,619

 

 

$

2,271,777

 

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share data)

(Unaudited)

 

 

Three months ended
April 30,

 

2020

 

2019

Revenues:

 

 

 

Subscription services

$

270,235

 

 

$

198,115

 

Professional services and other

66,871

 

 

46,637

 

Total revenues

337,106

 

 

244,752

 

Cost of revenues(3):

 

 

 

Cost of subscription services

43,212

 

 

30,378

 

Cost of professional services and other

51,668

 

 

35,125

 

Total cost of revenues

94,880

 

 

65,503

 

Gross profit

242,226

 

 

179,249

 

Operating expenses(3):

 

 

 

Research and development

62,237

 

 

44,973

 

Sales and marketing

55,755

 

 

39,617

 

General and administrative

36,669

 

 

23,490

 

Total operating expenses

154,661

 

 

108,080

 

Operating income

87,565

 

 

71,169

 

Other income, net

3,414

 

 

6,161

 

Income before income taxes

90,979

 

 

77,330

 

Provision for income taxes

4,409

 

 

3,881

 

Net income

$

86,570

 

 

$

73,449

 

 

 

 

 

Net income per share:

 

 

 

Basic

$

0.58

 

 

$

0.50

 

Diluted

$

0.54

 

 

$

0.47

 

 

 

 

 

Weighted-average shares used to compute net income per share:

 

 

 

Basic

149,541

 

 

146,708

 

Diluted

159,474

 

 

157,910

 

Other comprehensive income:

 

 

 

Net change in unrealized gains on available-for- sale investments

$

1,297

 

 

$

962

 

Net change in cumulative foreign currency translation loss

389

 

 

(702

)

Comprehensive income

$

88,256

 

 

$

73,709

 

_______________________

(3) Includes stock-based compensation as follows:

 

 

 

 

Cost of revenues:

 

 

 

Cost of subscription services

$

1,019

 

 

$

385

 

Cost of professional services and other

5,074

 

 

2,978

 

Research and development

11,401

 

 

6,325

 

Sales and marketing

8,192

 

 

5,152

 

General and administrative

11,221

 

 

5,916

 

Total stock-based compensation

$

36,907

 

 

$

20,756

 

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

Three months ended
April 30,

 

2020

 

2019

Cash flows from operating activities

 

 

 

Net income

$

86,570

 

 

$

73,449

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

7,878

 

 

3,900

 

Reduction of operating lease right-of-use assets

2,997

 

 

1,538

 

Accretion of discount on short-term investments

(11

)

 

(1,178

)

Stock-based compensation

36,907

 

 

20,756

 

Amortization of deferred costs

4,751

 

 

4,849

 

Deferred income taxes

(1,134

)

 

418

 

(Gain) Loss on foreign currency from mark-to-market derivative

93

 

 

(80

)

Bad debt recovery

(393

)

 

(153

)

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

154,160

 

 

139,510

 

Unbilled accounts receivable

(4,452

)

 

(5,244

)

Deferred costs

(3,342

)

 

(4,601

)

Income taxes payable

(1,850

)

 

338

 

Other current and long-term assets

551

 

 

(2,759

)

Accounts payable

(4,430

)

 

(416

)

Accrued expenses and other current liabilities

2,691

 

 

(759

)

Deferred revenue

1,477

 

 

7,914

 

Operating lease liabilities

(2,811

)

 

(1,629

)

Other long-term liabilities

2,520

 

 

436

 

Net cash provided by operating activities

282,172

 

 

236,289

 

Cash flows from investing activities

 

 

 

Purchases of short-term investments

(188,818

)

 

(228,894

)

Maturities and sales of short-term investments

140,342

 

 

188,965

 

Purchases of property and equipment

267

 

 

(1,194

)

Capitalized internal-use software development costs

?

 

 

(419

)

Net cash used in investing activities

(48,209

)

 

(41,542

)

Cash flows from financing activities

 

 

 

Reduction of lease liabilities - finance leases

(248

)

 

(249

)

Proceeds from exercise of common stock options

9,781

 

 

3,391

 

Net cash provided by financing activities

9,533

 

 

3,142

 

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

548

 

 

(702

)

Net change in cash, cash equivalents, and restricted cash

244,044

 

 

197,187

 

Cash, cash equivalents, and restricted cash at beginning of period

479,797

 

 

552,178

 

Cash, cash equivalents, and restricted cash at end of period

$

723,841

 

$

749,365

 

Non-GAAP Financial Measures

In Veeva's public disclosures, Veeva has provided non-GAAP measures, which it defines as financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. In addition to its GAAP measures, Veeva uses these non-GAAP financial measures internally for budgeting and resource allocation purposes and in analyzing its financial results. For the reasons set forth below, Veeva believes that excluding the following items provides information that is helpful in understanding its operating results, evaluating its future prospects, comparing its financial results across accounting periods, and comparing its financial results to its peers, many of which provide similar non-GAAP financial measures.

There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures provided by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by Veeva's management about which items are adjusted to calculate its non-GAAP financial measures. Veeva compensates for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in its public disclosures.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Veeva encourages its investors and others to review its financial information in its entirety, not to rely on any single financial measure to evaluate its business, and to view its non-GAAP financial measures in conjunction with the most directly comparable GAAP financial measures. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables below.

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(Dollars in thousands, except per share data)

(Unaudited)

 

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

 

 

Three months ended
April 30,

 

2020

 

2019

Cost of subscription services revenues on a GAAP basis

$

43,212

 

 

$

30,378

 

Stock-based compensation expense

(1,019

)

 

(385

)

Amortization of purchased intangibles

(1,594

)

 

(667

)

Cost of subscription services revenues on a non-GAAP basis

$

40,599

 

 

$

29,326

 

 

 

 

 

Gross margin on subscription services revenues on a GAAP basis

84.0

%

 

84.7

%

Stock-based compensation expense

0.4

 

 

0.2

 

Amortization of purchased intangibles

0.6

 

 

0.3

 

Gross margin on subscription services revenues on a non-GAAP basis

85.0

%

 

85.2

%

 

 

 

 

Cost of professional services and other revenues on a GAAP basis

$

51,668

 

 

$

35,125

 

Stock-based compensation expense

(5,074

)

 

(2,978

)

Amortization of purchased intangibles

(135

)

 

?

 

Cost of professional services and other revenues on a non-GAAP basis

$

46,459

 

 

$

32,147

 

 

 

 

 

Gross margin on professional services and other revenues on a GAAP basis

22.7

%

 

24.7

%

Stock-based compensation expense

7.6

 

 

6.4

 

Amortization of purchased intangibles

0.2

 

 

?

 

Gross margin on professional services and other revenues on a non-GAAP basis

30.5

%

 

31.1

%

 

 

 

 

Gross profit on a GAAP basis

$

242,226

 

 

$

179,249

 

Stock-based compensation expense

6,093

 

 

3,363

 

Amortization of purchased intangibles

1,729

 

 

667

 

Gross profit on a non-GAAP basis

$

250,048

 

 

$

183,279

 

 

 

 

 

Gross margin on total revenues on a GAAP basis

71.9

%

 

73.2

%

Stock-based compensation expense

1.8

 

 

1.4

 

Amortization of purchased intangibles

0.5

 

 

0.3

 

Gross margin on total revenues on a non-GAAP basis

74.2

%

 

74.9

%

 

 

 

 

Research and development expense on a GAAP basis

$

62,237

 

 

$

44,973

 

Stock-based compensation expense

(11,401

)

 

(6,325

)

Amortization of purchased intangibles

(28

)

 

?

 

Research and development expense on a non-GAAP basis

$

50,808

 

 

$

38,648

 

 

 

 

 

Sales and marketing expense on a GAAP basis

$

55,755

 

 

$

39,617

 

Stock-based compensation expense

(8,192

)

 

(5,152

)

Amortization of purchased intangibles

(3,402

)

 

(903

)

Sales and marketing expense on a non-GAAP basis

$

44,161

 

 

$

33,562

 

 

 

 

 

General and administrative expense on a GAAP basis

$

36,669

 

 

$

23,490

 

Stock-based compensation expense

(11,221

)

 

(5,916

)

Amortization of purchased intangibles

(56

)

 

?

 

General and administrative expense on a non-GAAP basis

$

25,392

 

 

$

17,574

 

 

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (continued)

(Dollars in thousands, except per share data)

(Unaudited)

 

 

Three months ended
April 30,

 

2020

 

2019

Operating expense on a GAAP basis

$

154,661

 

 

$

108,080

 

Stock-based compensation expense

(30,814

)

 

(17,393

)

Amortization of purchased intangibles

(3,486

)

 

(903

)

Operating expense on a non-GAAP basis

$

120,361

 

 

$

89,784

 

 

 

 

 

Operating income on a GAAP basis

$

87,565

 

 

$

71,169

 

Stock-based compensation expense

36,907

 

 

20,756

 

Amortization of purchased intangibles

5,215

 

 

1,570

 

Operating income on a non-GAAP basis

$

129,687

 

 

$

93,495

 

 

 

 

 

Operating margin on a GAAP basis

26.0

%

 

29.1

%

Stock-based compensation expense

11.0

 

 

8.5

 

Amortization of purchased intangibles

1.5

 

 

0.6

 

Operating margin on a non-GAAP basis

38.5

%

 

38.2

%

 

 

 

 

Net income on a GAAP basis

$

86,570

 

 

$

73,449

 

Stock-based compensation expense

36,907

 

 

20,756

 

Amortization of purchased intangibles

5,215

 

 

1,570

 

Income tax effect on non-GAAP adjustments(1)

(23,542

)

 

(17,047

)

Net income on a non-GAAP basis

$

105,150

 

 

$

78,728

 

 

 

 

 

Diluted net income per share on a GAAP basis

$

0.54

 

 

$

0.47

 

Stock-based compensation expense

0.23

 

 

0.13

 

Amortization of purchased intangibles

0.04

 

 

0.01

 

Income tax effect on non-GAAP adjustments(1)

(0.15

)

 

(0.11

)

Diluted net income per share on a non-GAAP basis

$

0.66

 

 

$

0.50

 

________________________

(1)

For the three months ended April 30, 2020 and 2019, management used an estimated annual effective non-GAAP tax rate of 21.0%.

 


These press releases may also interest you

at 03:52
The progressive decrease in hearing in elderly people can represent a major problem for their quality of life: it has in fact been demonstrated that critical issues such as these, in addition to being a problem as such, can...

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...



News published on and distributed by: